CLOs on the Move


 
Aeluma develops novel optoelectronic devices for sensing and communications applications. Aeluma has pioneered a technique to manufacture devices using high performance compound semiconductor materials on large-diameter silicon wafers that are commonly used for mass market microelectronics. The technology has the potential to enhance performance and provide a path to cost-effective, large-scale manufacturing, both of which are critical for future LiDAR and other sensor applications. Aeluma is developing a streamlined business model from its headquarters in Santa Barbara, California that has a state-of-the-art manufacturing cleanroom.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aeluma.com
  • 27 Castilian Drive
    Goleta, CA USA 93117
  • Phone: 805.351.2707

Executives

Name Title Contact Details

Similar Companies

The Athena Group

The Athena Group is a Gainesville, FL-based company in the Computers and Electronics sector.

ODYSSEY Technical Solutions

ODYSSEY Technical Solutions is a Round Rock, TX-based company in the Computers & Electronics sector.

Anchor Semiconductor

Anchor Semiconductor is a Santa Clara, CA-based company in the Computers and Electronics sector.

CHiL Semiconductor Corp

CHiL Semiconductor Corp is a Tewksbury, MA-based company in the Computers and Electronics sector.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.